cAMP-dependent Tyrosine Phosphorylation of Subunit I Inhibits Cytochrome c Oxidase Activity*
- Icksoo Lee‡,
- Arthur R. Salomon§¶,
- Scott Ficarro§,
- Isabella Mathes∥,
- Friedrich Lottspeich∥,
- Lawrence I. Grossman‡ and
- Maik Hüttemann‡,**
- ‡Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan 48201, the §Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, and the ∥Max Planck Institute of Biochemistry, D-82152 Martinsried, Germany
- ↵** To whom correspondence should be addressed: Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, 540 E. Canfield Ave., Detroit, MI 48201. Tel.: 313-577-9150; Fax: 313-577-5218; E-mail: mhuttema{at}med.wayne.edu.
Abstract
Signaling pathways targeting mitochondria are poorly understood. We here examine phosphorylation by the cAMP-dependent pathway of subunits of cytochrome c oxidase (COX), the terminal enzyme of the electron transport chain. Using anti-phospho antibodies, we show that cow liver COX subunit I is tyrosinephosphorylated in the presence of theophylline, a phosphodiesterase inhibitor that creates high cAMP levels, but not in its absence. The site of phosphorylation, identified by mass spectrometry, is tyrosine 304 of COX catalytic subunit I. Subunit I phosphorylation leads to a decrease of Vmax and an increase of Km for cytochrome c and shifts the reaction kinetics from hyperbolic to sigmoidal such that COX is fully or strongly inhibited up to 10 μm cytochrome c substrate concentrations, even in the presence of allosteric activator ADP. To assess our findings with the isolated enzyme in a physiological context, we tested the starvation signal glucagon on human HepG2 cells and cow liver tissue. Glucagon leads to COX inactivation, an effect also observed after incubation with adenylyl cyclase activator forskolin. Thus, the glucagon receptor/G-protein/cAMP pathway regulates COX activity. At therapeutic concentrations used for asthma relief, theophylline causes lung COX inhibition and decreases cellular ATP levels, suggesting a mechanism for its clinical action.
- Received October 4, 2004.
- Revision received November 15, 2004.
- The American Society for Biochemistry and Molecular Biology, Inc.











